Is there evidence for different effects among EGFR-TKIs? Systematic review and meta-analysis of EGFR tyrosine kinase inhibitors (TKIs) versus chemotherapy as first-line treatment for patients harboring EGFR mutations

Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6

“…Именно по этой причине была проведена серия метаанализов для выявления наиболее эффективного препарата из указанной выше группы. Данные исследования не определили никаких значимых различий в эффективности гефитиниба, эрлотиниба и афатиниба, но указывали на разницу профилей нежела-тельных явлений [23][24][25].…”

Non–Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology

“…16,147 Erlotinib and gefitinib are orally active TKIs that are very well tolerated by most patients. 148,149 An analysis of 5 clinical trials in patients, mainly from the Western hemisphere (n=223), with advanced NSCLC (stage IIIB or IV) found that those with sensitizing EGFR mutations who received TKIs had a 67% response rate and an OS of approximately 24 months. 150 The TORCH trial suggested that EGFR mutation testing should be performed in patients with advanced nonsquamous NSCLC.…”

EGFR inhibition in NSCLC: New findings…. and opened questions?

“…Two first-generation, reversible TKIs, gefitinib and erlotinib, and one second-generation, irreversible, pan-Her TKI, afatinib. These compounds have shown similar efficacy in studies and meta-analysis which indirectly compared them, reaching an efficacy plateau in both PFS (10-12 months) and OS (ranging from 21 to 30 months) (Haspinger et al, 2015). Afatinib is the only compound showing a significant OS benefit in the recent pooled analysis of both LuxLung3 (LL3) and LuxLung6 (LL6) trials, even if limited to the subgroup of patients with EGFR exon 19 deletion (Yang et al, 2015a).…”